@article{ZhangSharmaWeiheretal.2021, author = {Zhang, Ying and Sharma, Amit and Weiher, Hans and Schmid, Matthias and Kristiansen, Glen and Schmidt-Wolf, Ingo G. H.}, title = {Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials}, journal = {Cancers}, volume = {13}, number = {23}, issn = {2072-6694}, doi = {10.3390/cancers13236007}, institution = {Fachbereich Wirtschaftswissenschaften}, pages = {6007}, year = {2021}, abstract = {Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.}, language = {en} }